Tumor Necrosis Factor

Patients with plaque psoriasis experienced greater efficacy with guselkumab compared with fumaric acid esters, according to a study.

While certain demographic factors were associated with a higher risk for paradoxical eczema among patients with psoriasis, treatment with certain biologic classes was not, according to a study.

The introduction of TNF inhibitors in 2003 has failed to stop fracture rates in patients with ankylosing spondylitis from more than doubling from 2000 to 2020, according to data published in Arthritis Care & Research.

Investigators identified tumor necrosis factor receptor 1 as the most frequently studied plasma biomarker in the setting of chronic kidney disease progression.

Ozoralizumab, in either the 30 mg or 80 mg formulation, significantly reduces rheumatoid arthritis signs and symptoms in patients with an inadequate response to methotrexate, according to data published in Arthritis & Rheumatology.

SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age.

SAN DIEGO — A novel blood protein panel correlated with tumor necrosis factor antagonist treatment failure had modest predictive capacity among patients newly diagnosed with Crohn’s disease, according to research.